Cardiovascular Diseases Clinical Trial
Official title:
Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the follow-up of subject's is not prescriptive in nature and is according to the judgment of the physician (investigator in the course of treatment for each patient), within the period of observation of 12 months. This includes an enrollment period of 6 months in which each subject will be observed for approximately 6 months. Examinations, diagnostic measures, findings and observations performed as per usual medical practice during the observation period will be recorded on Case Report Forms (CRFs) by the investigator or site staffs according to the protocol.
Status | Completed |
Enrollment | 128 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria - Male and female subject >18 years-old - Subjects with primary hyperlipidemia or mixed dyslipidemia with elevated levels of total cholesterol,, LDL-C (low-density lipoprotein-cholesterol), triglycerides and/or decreased levels of HDL-C (high-density lipoprotein-cholesterol) (< 40 mg/dL) and has demonstrated an inadequate response to a lipid-restricted diet and other non-pharmacologic measures alone such as exercise - Subject has demonstrated persistent dyslipidemic values and/or inadequate response or intolerance to other pharmacologic therapies such as statins, fibrates, resins, etc. - Female subjects with reproductive potential must use an approved contraceptive method (intrauterine device (IUD), birth control pills or barrier device) during and for 3 months after discontinuation of study treatment. Exclusion Criteria - Subject has been treated with any other investigational product in the last 30 days before the day of the screening visit - Subject exhibits signs of acute illness with clinically relevant findings in the pre-study examination - Subject has known hypersensitivity to niacin or any component of NiaspanĀ® - Subject has significant or unexplained hepatic and/or renal dysfunction - Subject has active peptic ulcer disease - Subject exhibits active arterial bleeding - Subject is pregnant or lactating - The mental condition of the subject renders him/her unable to understand the nature, scope, and possible consequences of the study - Subject is unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Colombia | Site Reference ID/Investigator# 48182 | Cali | |
Colombia | Site Reference ID/Investigator# 48183 | Cali | |
Mexico | Site Reference ID/Investigator# 42108 | Aguascalientes | |
Mexico | Site Reference ID/Investigator# 42110 | Aguascalientes | |
Mexico | Site Reference ID/Investigator# 42103 | Guadalajara, Jalisco | |
Mexico | Site Reference ID/Investigator# 42105 | Metepec, Estado de Mexico | |
Mexico | Site Reference ID/Investigator# 42102 | Mexico City DF | |
Mexico | Site Reference ID/Investigator# 42106 | Mexico City DF | |
Mexico | Site Reference ID/Investigator# 42107 | Mexico City DF | |
Mexico | Site Reference ID/Investigator# 42109 | Mexico City DF | |
Mexico | Site Reference ID/Investigator# 26348 | Mexico D.F. | |
Mexico | Site Reference ID/Investigator# 42104 | Tijuana, Baja California Norte | |
Mexico | Site Reference ID/Investigator# 42112 | Tijuana, Baja California Norte | |
Mexico | Site Reference ID/Investigator# 42111 | Tuxtla Gutierrez, Chiapas | |
Mexico | Site Reference ID/Investigator# 42114 | Tuxtla Gutierrez, Chiapas | |
Mexico | Site Reference ID/Investigator# 42113 | Zacatecas | |
Mexico | Site Reference ID/Investigator# 42115 | Zapopan, Jalisco | |
Venezuela | Site Reference ID/Investigator# 44202 | Bolivar | |
Venezuela | Site Reference ID/Investigator# 26350 | Caracas | |
Venezuela | Site Reference ID/Investigator# 44203 | Caracas | |
Venezuela | Site Reference ID/Investigator# 44206 | Caracas | |
Venezuela | Site Reference ID/Investigator# 44204 | Estado Carabobo |
Lead Sponsor | Collaborator |
---|---|
Abbott | QUASY |
Colombia, Mexico, Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness of Niaspan | Increasing serum HDL-C (high-density lipoprotein - cholesterol) levels. Calculated change in different variables (Difference percent for HDL, LDL, Non-HDL and Triglycerides) was obtained using the expression: percent.change=((final.visit.variable-baseline.variable.))/(baseline.variable))*100 Then percent change is calculated at 24 weeks regarding baseline for different variables. |
24 weeks regarding baseline visit (visit1) | No |
Secondary | Evaluate Changes Induced by Niaspan at the Completion of the Study Against Base Line Values | Evaluation of changes in non-HDL-C (non-high-density lipoproteins-cholesterol) lipids, LDL- C (low-density lipoproteins-cholesterol), total cholesterol and triglycerides (including in subjects with high triglycerides = 200 mg/dL), and the impact on the Framingham score | every 4 to 8 weeks for 24 weeks | No |
Secondary | Frequency of Flushing Events | evaluate occurrence of such events over time | every 4 weeks for 24 weeks | Yes |
Secondary | Overall Safety and Tolerability of Niaspan | Evaluate overall safety of Niaspan through evaluation of adverse events | every 4 weeks for 24 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|